Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P08218
UPID:
CEL2B_HUMAN
Alternative names:
Elastase-2B
Alternative UPACC:
P08218; Q14D16; Q6ISM5; Q96QV5
Background:
Chymotrypsin-like elastase family member 2B, also known as Elastase-2B, is a crucial enzyme that acts upon elastin, a key protein in the connective tissue. This enzyme's activity is essential for the proper functioning and maintenance of elastic fibers, which provide flexibility and strength to various tissues.
Therapeutic significance:
Understanding the role of Chymotrypsin-like elastase family member 2B could open doors to potential therapeutic strategies. Its involvement in the breakdown and remodeling of elastin suggests a pivotal role in tissue repair and regeneration processes.